natgillin/translations-raw huggingface dataset:
The younger children had a higher weight-normalized Cl/F (214 mL/h/kg) compared with the adolescents (136 mL/h/kg).
Mlajši otroci so imeli višjo vrednost CL/F (214 ml/h/kg), normaliziranega na telesno maso, v primerjavi z mladostniki (136 ml/h/kg).
The Zevalin therapeutic regimen was administered in two steps (see 4.2).
Terapija z zdravilom Zevalin je potekala v dveh fazah (glejte poglaveje 4.2).
The ziconotide dose should be reduced or discontinued if signs or symptoms of cognitive impairment or neuropsychiatric adverse reactions develop, but other contributing causes should also be considered.
Če se razvijejo znaki ali simptomi poslabšanja kognitivnih sposobnosti ali nevropsihiatrični neželeni učinki, je potrebno odmerek zikonotida zmanjšati ali z uporabo zdravila prenehati, vendar je potrebno upoštevati tudi druge vzroke, ki k motnji lahko prispevajo.
The Zonegran orodispersible tablet should be placed in the mouth on the tongue, where it will rapidly disperse in saliva.
Bolnik naj Zonegran orodisperzibilno tableto v ustih položi na jezik, kjer se bo hitro razpustila v slini.
The α4β7 integrin is expressed on a discrete subset of memory T helper lymphocytes which preferentially migrate into the gastrointestinal (GI) tract and cause inflammation that is characteristic of ulcerative colitis and Crohn’s disease, both of which are chronic inflammatory immunologically mediated conditions of the GI tract.
Integrin α4β7 je izražen na posebni podskupini spominskih celic T pomagalk, ki migrirajo predvsem v gastrointestinalni (GI) trakt in povzročajo vnetje, značilno za ulcerozni kolitis in Crohnovo bolezen, imunološko pogojeni kronični vnetni bolezni gastrointestinalnega trakta.
The ‘agreement rates’ between the first and second scans were similar regardless of which of the two medicines were used for the second scan.
Stopnje ujemanja med prvim in drugim slikanjem so bile podobne, ne glede na to, katero zdravilo je bilo uporabljeno za drugo slikanje.
The ‘class’ reflects the seriousness of the disease: patients with class II PAH have slight limitation of physical activity and those with class III disease have marked limitation of physical activity.
„Razred“ opredeljuje resnost bolezni: bolniki s PAH razreda II imajo rahlo omejeno telesno zmogljivost, bolniki s PAH razreda III pa izrazito omejeno telesno zmogljivost.
The ‘class’ reflects the seriousness of the disease: ‘class III’ involves marked limitation of physical activity.
Funkcijski razred odraža resnost bolezni: razred III pomeni izrazito omejeno fizično zmogljivost.
The ‘class’ reflects the seriousness of the disease: ‘class III’ involves marked limitation of physical activity.
„Razred“ odraža resnost bolezni: „razred III“ vključuje izrazito omejitev fizične dejavnosti.
The ‘class’ reflects the seriousness of the disease: ‘class III’ involves marked limitation of physical activity.
„Razred‟ opredeljuje resnost bolezni: „razred III‟ označuje izrazito omejeno telesno zmogljivost.
The ‘class’ reflects the seriousness of the disease: ‘class II’ involves slight limitation of physical activity and ‘class III’ involves marked limitation of physical activity.
Funkcijski razred odraža resnost bolezni: razred II pomeni rahlo omejitev telesne zmogljivosti, razred III pa znatno omejitev telesne zmogljivosti.
The ‘class’ reflects the seriousness of the disease: ‘class II’ involves slight limitation of physical activity and ‘class III’ involves marked limitation of physical activity.
Razred odraža resnost bolezni: razred II pomeni rahlo omejitev telesne zmogljivosti, razred III pa znatno omejitev telesne zmogljivosti.
The ‘class’ reflects the severity of the disease: ‘class II’ involves slight limitation of physical activity while ‘class III’ involves marked limitation of physical activity.
Funkcionalni razred odraža resnost bolezni: razred II pomeni rahlo omejitev telesne zmogljivosti, razred III pa znatno omejitev telesne zmogljivosti.
The ‘high’ doses of Zypadhera were more effective at preventing a worsening of symptoms than the ‘low’ dose.
Visoki odmerki zdravila Zypadhera so bili bolj učinkoviti pri preprečevanju poslabšanja simptomov kot nizki odmerki.
The ‘N-dealkylated acid’ (NW-1689) undergoes conjugation with glucuronic acid yielding its acyl glucuronide.
„N-dealkilirana kislina“ (NW-1689) se prek konjugacije z glukuronsko kislino pretvori v njen acil-glukuronid.
The ‘P’ symbol disappears from the display, when the nasal spray is primed again, by spraying once.
Ko razpršite enkrat v zrak, simbol »P« izgine z zaslona in pršilo za nos je ponovno pripravljeno za uporabo.
The ‘treatment initiation pack’ is clearly labelled to make sure you take the correct tablet at the correct time.
‘Pakiranje za začetek zdravljenja’ je jasno označeno, da boste zagotovo vzeli pravo tableto ob pravem času.
The ‘treatment initiation pack’ will also contain enough tablets for another 8 days at the recommended dose (Days 7 to 14).
‘Pakiranje za začetek zdravljenja’ bo vsebovalo tudi dovolj tablet še za nadaljnjih 8 dni ob priporočenem odmerku (7. do 14. dan).
the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye.
„vlažno“ obliko starostne degeneracije makule (SDM), tj. bolezni, ki prizadene osrednji del mrežnice (imenovan makula) v zadnjem delu očesa.
the ‘wet’ form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye.
„vlažno“ obliko starostne degeneracije makule (SDM), tj. bolezni, ki prizadene središčni del mrežnice (imenovan makula) v zadnjem delu očesa.
The “Discard by” date should be written on the inhaler label in the space provided.
V predvideni prostor na nalepki inhalatorja naj bolnik vpiše datum "Zavrzite do".
The “Discard by” date should be written on the inhaler label in the space provided.
V predvideni prostor na nalepki inhalatorja naj bolnik vpiše datum “Zavrzite do“.
The “Irbesartan Diabetic Nephropathy Trial (IDNT)” shows that irbesartan decreases the progression of renal disease in patients with chronic renal insufficiency and overt proteinuria.
Preskušanje irbesartana pri diabetični nefropatiji –“Irbesartan Diabetic Nephropathy Trial" (IDNT) kaže, da irbesartan pri bolnikih s kronično ledvično insuficienco in izraženo proteinurijo zmanjša napredovanje ledvične bolezni.
The “Patient DVD”
»DVD za bolnika«.
The “Physician DVD”
»DVD za zdravnika«,
Their breathing should be monitored for up to three days after vaccination.
Njihovo dihanje je potrebno nadzorovati do tri dni po cepljenju.
Their breathing should be monitored for up to three days after vaccination.
Njihovo dihanje je treba nadzorovati do tri dni po cepljenju.
Their co-administration is contraindicated (see section 4.3).
Sočasno jemanje omenjenih zdravil je kontraindicirano (glejte poglavje 4.4).
Their effect is essentially confined to rapidly dividing organisms.
Ta učinek je omejen na hitro deleče se organizme.
Their frequencies were established based on data from intravenous administration of sufentanil: common – muscle twitching; uncommon – hypersensitivity, apathy, nervousness, ataxia, dystonia, hyperreflexia, heart rate decreased and dry skin.
Pogostnosti so bile določene na osnovi podatkov iz intravenskega dajanja sufentanila: pogosti – trzanje mišic; občasni – preobčutljivost, apatija, živčnost, ataksija, distonija, hiperrefleksija, upočasnjen srčni utrip in suha koža.
Their frequency is defined using the following conventions: common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000).
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) not known (cannot be estimated from the available data).
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000) , neznani (ni mogoče oceniti iz razpoložljivih podatkov).
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov.
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
Their frequency is defined using the following conventions: common (1/100 to <1/10); uncommon (1/1,000 to < 1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000).
Njihova pogostnost je navedena po naslednjem dogovoru: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
Their frequency is defined using the following conventions: common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Njihova pogostnost je navedena po naslednjem dogovoru: pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznani (ni mogoče oceniti iz razpoložljivih podatkov).
Their frequency is defined using the following conventions: common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000).
Njihova pogostnost je navedena po naslednjem dogovoru: pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000).
Their frequency is presented in Table 1, adverse drug reactions using Council for International Organizations of Medical Sciences (CIOMS III), listed by MedDRA System Organ Class (SOC) and at the preferred term level and then by frequency classification.
Njihova pogostnost je prikazana v Preglednici 1, neželeni učinki zdravila z uporabo CIOMS III (Council for International Organizations of Medical Sciences) ter navajanja po organskih sistemih (SOC – System Organ Class) po MedDRA na ravni prednostnega termina in nato po razvrstitvi pogostnosti.
Their frequency is presented using CIOMS III frequency classification and then listed by MedDRA System Organ Class (SOC) and at the preferred term level.
Njihova pogostnost je predstavljena z uporabo razvrstitve pogostnosti CIOMS III ter so navedeni po organskem sistemu po MedDRA in ravni prednostnega izraza.
Their JIA subtypes at disease onset were: Oligoarticular (16%), Polyarticular (64%; 20% of the total were rheumatoid factor positive), and Systemic (20%).
Podtipi juvenilnega idiopatskega artritisa ob začetku bolezni so bili: oligoartikularni (16%), poliartikularni (64%; 20% vseh je bilo pozitivnih na revmatoidni faktor) in sistemski (20%).
Their piglets then become immunised (protected against PCV2) when they drink the colostrum (first milk) from their vaccinated mothers.
Njihovi pujski postanejo s pitjem kolostruma (prvega mleka) cepljenih samic imuni (zaščiteni proti cirkovirusu PCV2).
Their piglets then become immunised when they drink the colostrum (first milk).
Njihovi pujski postanejo ob sesanju kolostruma (prvega mleka) imuni.
Their prescribing physician will provide training on the following elements:
Zdravnik, ki predpiše zdravilo, mora zagotoviti usposabljanje o naslednjih elementih:
Their prescribing physician will provide training on the following elements: Precaution for storage
Zdravnik, ki je predpisal zdravilo, bo poskrbel za izobraževanje o naslednjih elementih: Navodila za shranjevanje,
Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation.
Za njihovo prejemanje, shranjevanje, uporabo, prenos in odstranjevanje veljajo predpisi in/ali ustrezne licence pristojnega organa.
Their results closely paralleled the results obtained in the pivotal trial.
Njihovi rezultati so ustrezali rezultatom, dobljenim v ključni študiji.
Thelin 100 mg film-coated tablets are yellow-to-orange, capsule-shaped tablets, marked with T-100 on one side.
Thelin 100 mg filmsko obložene tablete so rumene do oranžne barve v obliki kapsule z napisom T-100 na eni strani.
Thelin is contraindicated in patients with elevated liver aminotransferases prior to initiation of treatment (> 3 x ULN), or with elevated direct bilirubin > 2 x ULN prior to initiation of treatment, see section 4.3.
Zdravilo Thelin je kontraindicirano za zdravljenje bolnikov, ki imajo pred začetkom zdravljenja zvišane vrednosti jetrnih amintransferaz (> 3× ZMN), ali, ki imajo pred začetkom zdravljenja zvišane vrednosti direktnega bilirubina > × 2 ZMN, glejte poglavje 4.3.
Thelin is to be taken orally as a dose of 100 mg once daily.
Thelin se jemlje peroralno v odmerku 100 mg enkrat na dan.
Thelin is used in patients with class III disease.
Zdravilo Thelin se uporablja pri bolnikih z boleznijo razreda III.
them to hyperkalaemia or
hiperkaliemiji, in pri
Then administer TREVICTA (into deltoida or gluteal muscle)
Nadaljujte z odmerjanjem zdravila TREVICTA (v deltoidnoa ali glutealno mišico)
Then change the position of the vial adapter.
Nato premaknite adapter za vialo.
Then choose a different injection site and finish taking the injection.
Nato izberite drugo mesto injiciranja in si dajte injekcijo.
Then CLcr is adjusted for body surface area (BSA) as follows:
CLcr je prilagojen na telesno površino (BSA – »body surface area«) na sledeč način:
Then CLcr is adjusted for body surface area (BSA) as follows:
CLcr je prilagojen na telesno površino (BSA –»body surface area«) na sledeč način:
Then CLcr is adjusted for body surface area (BSA) as follows:
CLcr je prilagojen na telesno površino (BSA– »body surface area«) na sledeč način:
Then CLcr is adjusted for body surface area (BSA) as follows: CLcr (ml/min)
CLcr je prilagojen na telesno površino (BSA-»body surface area«) na sledeč način: CLcr (ml/min)
then continue therapy for at least
nadaljujte s terapijo še
then continue therapy for at least
nato nadaljujte s terapijo še
Then continue with your normal schedule.
Nato nadaljujte z jemanjem zdravila po običajnem razporedu.
Then continue with your regular schedule of patch-change days, even if this means discarding a patch after you have worn it for less than 3-4 days.
Nato nadaljujte reden razpored menjave obliža, tudi če boste obliž zavrgli potem, ko ste ga imeli manj kot 3–4 dni.
Then continue your treatment as before.
Nato nadaljujte z vašim zdravljenjem kot pred tem.
Then disconnect the syringe (with needle) from the device.
S pripomočka nato brizgo (z iglo) odstranite.
Then draw up solution as far as the mark on the syringe:
Potegnite raztopino kot je označeno na injekcijski brizgi:
Then drink a large glass of water or any other drink.
Nato spijte velik kozarec vode ali drugega napitka.
Then drink it straight away.
Potem takoj popijte.
Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest.
Potem pojejte še sadje, kekse ali sendvič, kot vam je svetoval vaš zdravnik, in počivajte.
Then give the next dose of Aptivus and ritonavir at the regularly scheduled time.
Naslednji odmerek zdravila Aptivus in ritonavirja naj vzame kot običajno.
Then GONAL-f is started approximately two weeks after start of agonist treatment.
Nato se približno dva tedna po začetku zdravljenja z agonistom začne zdravljenje z zdravilom GONAL-f.
Then grip the outer needle cap and unscrew the needle.
Primite zunanji pokrovček igle in odvijte iglo.
Then hold the syringe vertically and the needle upwards, and gently push the plunger upwards.
Nato injekcijsko brizgo držite v navpičnem položaju z injekcijsko iglo navzgor, nato pa rahlo pritisnite bat navzgor.
Then IMMEDIATELY (within 2 minutes) inject the pH-adjusted liposomes into the vial of heated reconstituted Myocet doxorubicin HCl.
Nato NEMUDOMA (v največ 2 minutah) injicirajte liposome z uravnano vrednostjo pH v vialo z ogretim, rekonstituiranim Myocet doksorubicinijevim kloridom.
Then increase to full dose if tolerated for the remainder of the course.
Če ga bolnik prenaša, povišajte do celotnega odmerka za preostali del cikla.
Then inject the following doses as originally instructed.
Z injiciranjem nato nadaljujte kot vam je na začetku določil zdravnik.
Then insert the needle through the rubber top of the PegIntron vial.
Nato zabodite iglo skozi gumijasti zgornji del viale zdravila PegIntron.
Then insert the needle through the rubber top of the ViraferonPeg vial.
Nato zabodite iglo skozi gumijasti zgornji del viale zdravila ViraferonPeg.
Then keep the syringe in position and let go of the pinch of skin.
Nato napolnjeno injekcijsko brizgo držite in spustite kožno gubo.
Then leave a week before using Avonex again.
Nato počakajte en teden, preden ponovno uporabite zdravilo Avonex.
Then leave a week before using Avonex Pen again.
Nato počakajte en teden, preden ponovno uporabite napolnjen injekcijski peresnik Avonex Pen.
Then lift off the cap.
Nato odstranite zaporko.
then monthly for 6 months weekly during one month whenever the dose was increased.
potem enkrat mesečno 6 mesecev, enkrat tedensko en mesec, kadar se poveča odmerek.
Then move the pen up and down 10 times between the two positions as shown, so the glass ball moves from one end of the cartridge to the other.
Potem injekcijski peresnik 10-krat obrnite gor in dol med obema položajema, kot je prikazano, tako da se steklena kroglica premika z enega konca injekcijskega vložka na drugega.
then once every 2 weeks for 16 weeks then once every 4 weeks after that
naslednjih 16 tednov ga boste prejemali enkrat na 2 tedna, nato ga boste prejemali enkrat na 4 tedne.
Then open it by turning the mouth-piece in the direction of the arrow on the inhaler.
Nato ga odprite tako, da zavrtite ustnik v smeri puščice na inhalatorju.
Then peel away half of the clear protective covering (see picture).
Nato odstranite polovico prozorne zaščitne plasti, kot prikazuje slika.
Then place the capped dosing syringe in the carrying case provided.
Napolnjeno brizgo nato položite v priloženo škatlo za hranjenje odmerne brizge.
Then press all the way in and hold.
Potem pritisnite do konca noter in držite.
Then press the plunger until all of the air (but none of the liquid) has been removed
Potem potisnite bat noter, da boste iz brizge iztisnili ves zrak (ampak nič tekočine).
Then prime the pen.
Nato pripravite peresnik.
Then pull needle-cap straight up.
Nato pokrovček igle povlecite naravnost navzgor.
Then pull out the liquid again.
Ponovno izvlecite raztopino.
Then pull out the water again.
Ponovno odvzemite vodo.
Then pull the needle from skin.
Nato izvlecite iglo iz kože.
Then push the plunger to inject all of the solution at a slow, steady rate (see Diagram 11).
Nato potisnite bat tako, da počasi in enakomerno injicirate vso raztopino (glejte sliko 11).
Then push the plunger to inject all of the solution at a slow, steady rate (see Diagram 14).
Nato potisnite bat tako, da počasi in enakomerno injicirate vso raztopino (glejte sliko 14).
Then push the plunger to inject all of the solution at a slow, steady rate (see Diagram 19).
Nato potisnite bat tako, da počasi in enakomerno injicirate vso raztopino (glejte sliko 19).
Then push the plunger to inject all of the solution at a slow, steady rate (see Diagram 4).
Nato potisnite bat tako, da počasi in enakomerno injicirate vso raztopino (glejte sliko 4).
Then push the plunger to remove any possible air bubble (figure 5B).
Nato potisnite bat navzgor, da odstranite morebitne zračne mehurčke (slika 5B).
Then put the PecFent bottle in the child-resistant storage container.
Nato shranite steklenico zdravila PecFent v vsebniku za shranjevanje z zaporko, varno za otroke.
Then remove the pen and needle.
Vzemite ven peresnik in iglo.
Then rinse with water.
Nato oba dela izperite z vodo.
Then seek medical advice straight away.
Potem takoj poišcite zdravniški nasvet.
Then shake the closed bottle well for about 1 minute.
Nato zaprto steklenico temeljito stresajte približno 1 minuto.
Then shake the closed bottle well for about another minute.
Nato temeljito stresajte zaprto steklenico še približno 1 minuto.
Then slowly count to 5
Potem počasi preštejte do 5
Then start a new monthly dosing schedule from that day.
Nato od tega dne z novim režimom mesečnega odmerjanja.
Then take a tablet every day until your doctor tells you to stop.
Potem zaužijte vsak dan po eno tableto, dokler vam zdravnik ne bo svetoval, da zdravilo prenehate jemati.
Then take off the inner needle shield and hold the pen with the needle pointing upwards.
Nato snemite notranji ščitnik igle in držite injekcijski peresnik tako, da gleda igla navzgor.
Then take off the other half of the covering
Nato odstranite še drugo polovico zaščitne plasti.
Then take out a capsule from the blister (only remove the capsule just before use).
Nato iz pretisnega omota vzemite kapsulo (kapsulo vzemite tik pred uporabo).
Then take the next dose of OLYSIO at the usual scheduled time.
Nato vzemite naslednji odmerek zdravila OLYSIO kot običajno.
Then take your next dose as you would have on your originally scheduled day, had you not forgotten a dose.
Nato upo- rabite naslednji odmerek, kot bi ga uporabili po prvotnem urniku injciranja, če ne bi pozabili odmerka.
Then take your next dose as you would have on your originally scheduled day, had you not forgotten a dose.
Nato uporabite naslednji odmerek, kot bi ga uporabili po prvotnem urniku injciranja, če ne bi pozabili odmerka.
Then take your next dose at the time you would normally take it.
Naslednji odmerek vzemite ob običajnem času.
Then take your next dose at your regular scheduled time.
Naslednji odmerek uporabite po vašem rednem razporedu.
Then take your next dose of Aptivus and ritonavir at the regularly scheduled time.
Naslednji odmerek zdravila Aptivus in ritonavirja vzemite ob običajnem času.
Then the drip will be started in another vein.
Nato je treba začeti z novim infundiranjem zdravila v drugo veno.
Then the injection button should be held down 10 seconds before withdrawing the needle from the skin.
Preden se igla potegne iz kože, je treba gumb za injiciranje držati pritisnjen 10 sekund.
Then the injection button should be pressed all the way in.
Potem je treba gumb za injiciranje pritisniti povsem do konca.
Then the injection button should be pressed all the way in.
Potem pritisnite gumb za injiciranje povsem do konca.
Then the patient must drink the recommended test meal (100 ml 100 % orange juice).
Nato boste morali popiti priporočen obrok (100 ml 100-% pomarančnega soka).
Then the patient must drink the recommended test meal (200 ml 100 % orange juice or 1 g citric acid in 200 ml water).
Nato boste morali popiti priporočen obrok (200 ml 100-% pomarančnega soka ali 1 g citronske kisline v 200 ml vode).
Then therapy may be started again after the episode is over.
Ko epizoda intrakranialne hipertenzije izzveni, se lahko zdravljenje ponovno uvede.
Then turn bottle and syringe upside down (figure ).
Nato obrnite steklenico in brizgo navzdol (slika ).
Then turn the bottle upside down, and withdraw the necessary volume.
Steklenico obrnite na glavo in izvlecite potrebno količino.